Foralumab is the world’s only fully human, anti-CD3 mAb in clinical development. Forbes contributing author, William A. Haseltine, highlighted foralumab in his article entitled "New T Cell Antibody Treatment Improves Outcomes for Covid Patients". Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.1About Tiziana Life SciencesTiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s lead candidate, intranasal foralumab, the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. For further inquiries:Tiziana Life Sciences LtdPaul Spencer, Business Development and Investor Relations+44 (0) 207 495 2379info@tizianalifesciences.comInvestors:Irina KofflerLifeSci Advisors, LLC646.970.4681ikoffler@lifesciadvisors.com_________________1https://www.pnas.org/doi/10.1073/pnas.2220272120

Source: Forbes March 17, 2023 11:40 UTC